There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

Pfizer is approaching a whole new era of growth after launching a record number of new products and putting a focus on its ...

In the latest trading session, Eli Lilly (LLY) closed at $753.98, marking a +1.57% move from the previous day. This move outpaced the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.3%, and ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute ...

Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer. The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he ...

Kyverna Therapeutics (KYTX) announced the appointment of Naji Gehchan, to Chief Medical and Development Officer, where he will lead the ...

PulteGroup is one of the largest publicly traded homebuilders in the United States. As mortgage rates have risen back over 7%, shares of PulteGroup have fallen. It is down 20.1% over the last 3 months ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic ...

Vertex Pharmaceuticals is an innovative powerhouse with a good stock to buy on the dip. You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have ...